Maria Menichincheri

USPTO Granted Patents = 28 (Patent Applications = 7)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 5.7

ph-index = 7

Forward Citations = 241(Granted Patents)

Company Filing History:

22 out of 138

Nerviano Medical Sciences S.r.l.

Farmitalia Carlo Erba S.r.l.

Pharmacia & Upjohn S.p.a.

patents

where one patent can have more than one assignee

Years Active: 1994-2020

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10682348 - Molecules for administration to ROS1 mutant cancer cells (2020-06-16),

2. 10561651 - Methods for treating neuroblastoma (2020-02-18),

3. 10231965 - Molecules for administration to ROS1 mutant cancer cells (2019-03-19),

4. 10221181 - 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors (2019-03-05),

5. 10081622 - Substituted indazole derivatives active as kinase inhibitors (2018-09-25),

6. 9682083 - Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors (2017-06-20),

7. 9670191 - Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors (2017-06-06),

8. 9616059 - Substituted indazole derivatives active as kinase inhibitors (2017-04-11),

9. 9604980 - Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors (2017-03-28),

10. 9255087 - Substituted indazole derivatives active as kinase inhibitors (2016-02-09),

11. 9102662 - Substituted indazole derivatives active as kinase inhibitors (2015-08-11),

12. 9085558 - Substituted indazole derivatives active as kinase inhibitors (2015-07-21),

13. 9056854 - Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors (2015-06-16),

14. 9029356 - Substituted indazole derivatives active as kinase inhibitors (2015-05-12),

15. 8906934 - Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors (2014-12-09),

Title: Maria Menichincheri: Innovator in Cancer Research

Introduction

Maria Menichincheri is a prominent inventor based in Milan, Italy, with a remarkable portfolio of 28 patents. Her innovative work primarily focuses on therapeutic methods and compounds for treating cancer, specifically targeting deregulated protein kinase activity.

Latest Patents

Among her latest contributions are two significant patents:

1. **Molecules for administration to ROS1 mutant cancer cells** - This patent covers substituted indazole derivatives, which may be useful in therapies aimed at cancer treatment. The invention includes a specification for the compounds' preparation and their pharmaceutical applications.

2. **Methods for treating neuroblastoma** - This patent describes innovative methods for treating neuroblastoma associated with deregulated protein kinase activity. It also includes the administration of the substituted indazole derivatives and their pharmacologically acceptable salts.

Career Highlights

Maria Menichincheri has made significant strides in her career, having worked at notable companies such as Nerviano Medical Sciences S.r.l. and Ignyta, Inc. Her expertise in cancer treatment innovation has positioned her as a leading figure in the field of pharmaceutical development.

Collaborations

Throughout her career, Maria has collaborated with talented professionals, including Ermes Vanotti and Paolo Orsini. These partnerships have further enhanced her research and the creation of valuable patents in the realm of cancer therapies.

Conclusion

Maria Menichincheri's extensive contributions to cancer research through her innovative patents demonstrate her commitment to advancing therapeutic approaches in the medical field. Her work continues to inspire ongoing research and development aimed at improving patient outcomes in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.